ESH MDS 2024 | The current treatment approaches for patients with VEXAS syndrome
Maël Heiblig
• 17 Apr 2024
Maël Heiblig, MD, Hôpital Lyon Sud, Lyon, France, discusses the current treatment approaches for patients with VEXAS syndrome, which include controlling inflammation, controlling the clone, and supportive care. Dr Heiblig hopes that prospective trials will be initiated in this patient population shortly to assess the safety and efficacy of the treatments being used, as no standard of care currently exists. This interview took place at the European School of Hematology 9th Translational Research Conference on Myelodysplastic Syndromes (ESH MDS) in Budapest, Hungary.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
